This document is a publication of a patent application filed by EVEREST MEDICINES (SINGAPORE) PTE. LTD. The application, identified as US20260085111A1, details compositions and methods involving antibodies that bind to SLIT2 and related substitution mutants. The filing date was September 18, 2023, and the publication date is March 26, 2026.

As this is a patent application, it does not impose immediate regulatory obligations or penalties on other entities. However, it signifies potential future intellectual property rights related to SLIT2 therapeutics. Companies operating in the pharmaceutical or biotechnology sectors, particularly those involved in drug development or antibody research, should be aware of this filing as it may impact their own research and development strategies or patent landscape.